SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Curocell Seeks to Amend CRC01 Phase 1/2 Trial

Curocell filed an application with South Korea’s Ministry of Food and Drug Safety on Oct. 27, 2026, to amend the Phase 1/2 trial of CRC01 (anbal-cel), a treatment for adult B-cell acute lymphoblastic leukemia.

SquawkNews Desk

Related stories

Dynamix Enters Liquidation After Failed Business Combination Dynamix, a special purpose acquisition company, entered liquidation after failing to complete a business combination. M impact | EQUITY | Oct 29, 2026, 04:25 PM UTC Midday Recap: Alphabet Misses Q3 Targets; Caterpillar Falls on Results and Guidance The headline reports Alphabet missed Q3 EPS and revenue targets, while Caterpillar shares fell after a Q3 revenue miss and tepid guidance. The body is truncated after noting that a M impact | EQUITY | Oct 29, 2026, 04:24 PM UTC RBC Expects Estee Lauder Fiscal Q1 Results to Meet Consensus RBC expects Estee Lauder to meet consensus for fiscal Q1 results. M impact | EQUITY | Oct 29, 2026, 04:23 PM UTC Noel Tata Retires as Trent Chairman, to Leave Five Other Boards Nov. 12 Tata has retired as chairman of Trent Limited and is due to step down from the boards of five other group companies on Nov. 12, under the group’s age-related retirement policies. H M impact | EQUITY | Oct 29, 2026, 04:22 PM UTC Adani Group and IHCL to Develop Eight Airport Hotels The partnership will add 2,000 rooms across brands over the next 3–4 years at airports in Mumbai, Ahmedabad, Lucknow and Guwahati. M impact | EQUITY | Oct 29, 2026, 04:22 PM UTC Milky Mist Q2 Revenue Rises 42% to ₹1,089 Crore; Profit Nearly Triples Milky Mist Dairy Food reported record quarterly revenue for Q2FY27, with net profit at ₹78 crore. Revenue from operations, gross profit and EBITDA also reached quarterly highs. M impact | EQUITY | Oct 29, 2026, 04:22 PM UTC